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Ursula A. White and Jacqueline M. Stephens*
Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803
Abstract
Gp130 cytokines are involved in the regulation of numerous biological processes, including
hematopoiesis, immune response, inflammation, cardiovascular action, and neuronal survival.
These cytokines share glycoprotein 130 as a common signal transducer in their receptor complex
and typically activate STAT3. Most gp130 cytokines have paracrine or endocrine actions, and
their levels can be measured in circulation in rodents and humans. In recent years, various
laboratories have conducted studies to demonstrate that gp130 cytokines can modulate adipocyte
development and function. Therefore, these studies suggest that some gp130 cytokines may be
viable anti-obesity therapeutics. In this review, we will summarize the reported effects of gp130
cytokines on adipocyte differentiation and adipocyte function. In addition, the modulation of
gp130 cytokines in conditions of obesity, insulin resistance, and Type 2 diabetes will be presented.
INTRODUCTION
The Interleukin (IL)-6 family of cytokines is a group of functionally and structurally related
proteins that includes Interleukin-6 (IL-6), Interleukin-11 (IL-11), Interleukin-27 (IL-27),
leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF),
cardiotrophin-1 (CT-1), novel neurotrophin-1/B cell stimulating factor-3 or cardiotrophin-
like cytokine (CLC), and neuropoietin (NP) (reviewed in [1]). These cytokines regulate a
variety of complex biological processes, including hematopoiesis, immune response,
inflammation, proliferation, differentiation, mammalian reproduction, cardiovascular action,
and neuronal survival [reviewed in [2]). Activation of all cytokines in the IL-6 family
involves signaling via the Janus Kinase/Signal Transducer and Activator of Transcription
(JAK/STAT) pathway. Typically STAT3 is activated and, to a lesser extent, STAT1
(reviewed in [2]). The IL-6 cytokine family can also activate other signaling pathways,
including the MAPK (mitogen-activated protein kinase) cascade, PI3K
(phosphatidylinositol-3 kinase), mTOR (mammalian target of rapamycin/p70 S6 kinase),
and AMPK (5' adenosine monophosphate-activated protein kinase) (reviewed in [3]).
The IL-6 family is commonly referred to as gp130 cytokines because all members of this
family utilize glycoprotein 130 as a common signal transducer within their receptor complex
that is required for signaling (reviewed in [4]). Though originally characterized as having
unique properties, gp130 cytokines are known to function in a pleiotropic and redundant
manner. The shared usage of signal transducers in the receptor complexes likely accounts
for the functional redundancy of gp130 cytokines in mediating biological effects. The
ubiquitous expression of gp130 facilitates the pleiotropic nature of these cytokines. The
differences in gp130 cytokine activity can be partially attributed to the use of additional
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receptor components that are utilized by each family member, including the LIF receptor
and the cytokine's specific α receptor. IL-6 and IL-11 initially bind to the IL-6 receptor α [5]
and IL-11 receptor α [6], respectively, and then the complex associates with a gp130
homodimer complex for signaling. IL-27 engages a gp130/WSX-1 heterodimeric receptor
complex [7]. LIF and CT-1 require the gp130/LIF receptor (LIFR) complex to mediate
signal transduction [8, 9]. CT-1 has been reported to recruit an alpha receptor [10], which to
date has not been characterized. OSM has been reported to utilize the gp130/LIFR complex
[11], and can alternatively utilize a gp130/OSM receptor (OSMR) complex [12]. However,
recent studies largely indicate that OSM primarily signals via the OSMR and not the LIFR.
Both CNTF and CLC utilize a signaling complex, including CNTFRα, gp130, and LIFR for
signal transduction [13; 14]. NP was also reported to utilize this tri-partite receptor complex
[15]; however, recent studies from our laboratory demonstrate that NP induced STAT3
activation is not mediated by LIFR signaling [16]. The receptor components for each gp130
cytokine are reviewed in Table 1.
In recent years, gp130 cytokines have become a focus of attention in the scientific
community, as they have been implicated as potential therapeutic targets in obesity
(reviewed in [3]). It is well documented that obesity is a risk factor for a variety of other
metabolic abnormalities, including Type 2 Diabetes Mellitus (T2DM). Therefore, the study
of adipose tissue, particularly the adipocyte, is central to understanding the pathogenesis of
obesity and related disorders. Numerous findings in the last decade have highlighted the
differential effects of gp130 cytokines on important adipocyte functions. Our studies and
others have shown that adipocytes in vitro and adipose tissue in vivo are responsive to gp130
cytokines [17–24] and exert differential effects on adipogenesis [22–30] and insulin action
[20–24; 27]. The mechanisms and complex interactions underlying gp130 cytokine action in
adipose tissue have not been fully elucidated. Further analyses are necessary to provide
insight to the diverse roles of the gp130 family and to understand their contribution to
metabolic disease states.
INTERLEUKIN-6
Interleukin-6 (IL-6) is a pleiotropic cytokine that regulates various physiological processes
in multiple tissues, including inflammation, hematopoiesis, immune responses, and host
defense mechanisms (reviewed in [31]). Because an estimated one-third of the total basal
IL-6 concentration in healthy humans is estimated to originate from adipose tissue [32], IL-6
is considered an adipokine. Adipocytes produce and secrete only a fraction of adipose tissue
IL-6 [33], and it is well established that other cell types in adipose tissue are capable of IL-6
production [34; 35]. In the last decade, IL-6 has been intensely investigated and implicated
as a major player in the regulation of metabolic disease states.
Data regarding the role of IL-6 in both obesity and insulin resistance are controversial and
unresolved (reviewed in [36–38]). Though characterized as both a pro- and anti-
inflammatory cytokine, IL-6 is well recognized as a mediator of the low-grade chronic
inflammatory state of obesity (reviewed in [31]). Numerous studies have shown that IL-6
levels are greatly elevated in obese humans and strongly correlated with increased body
mass index (BMI) and waist circumference [39–42]. IL-6 has been implicated as a marker
for visceral adipose tissue [43; 44] because visceral adipose tissue releases more IL-6 than
subcutaneous adipose tissue [33; 35]. Conversely, one of the most striking observations
highlighting the anti-obesogenic effects of IL-6 was that knockout mice (IL-6−/−)
developed mature onset obesity, hypertriglyceridemia, and glucose intolerance [45].
However, this phenotype was not observed in other studies where IL-6 deficient mice did
not develop age-related obesity or metabolic syndrome [46]. Overall, the fact that IL-6 is
released from adipose tissue into systemic circulation and can positively correlate with
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obesity and percent body fat implicates a possible role for IL-6 in regulating body weight
and lipid metabolism.
Increasing data suggest that elevated plasma IL-6 is also associated with obesity-related
insulin resistance. The most recent human studies demonstrate that increased IL-6 levels
correlate with obesity (BMI) and are not necessarily associated with the Type 2 diabetic
state [47]. Yet, another study indicates IL-6 levels are higher in subjects with obesity-related
insulin resistance [48]. Other findings indicate that increased IL-6 concentrations are related
to adiposity and fat mass but not to insulin action or responsiveness [49; 50]. Hence, high
circulating levels of IL-6 may not be present in non-obese T2DM patients, and these studies
suggest that the relationship between IL-6 and insulin resistance seems to be mediated
through obesity. However, there are a number of studies both in vitro and in vivo that
demonstrate that IL-6 is capable of inducing insulin resistance. Though many of the in vivo
insulin resistant properties of IL-6 are characterized in the rodent liver [51–56], IL-6 can
also induce insulin resistance in cultured murine adipocytes by inhibiting glucose uptake and
impairing insulin signaling and action [20; 21]. Whether or not IL-6 impairs insulin action in
adipose tissue in vivo has yet to be clearly determined. The notion that IL-6 induces insulin
resistance is challenged by several findings demonstrating the production [57] and release
[58; 59] of IL-6 from contracting human skeletal muscle cells due to physical exercise, a
known insulin sensitizer [60; 61]. Overall, persistent secretion and circulation of IL-6 in
states of chronic inflammation, such as obesity, may promote insulin resistance. Hence, IL-6
plasma concentrations combined with other factors may be used as a predictor for the
development of T2DM [62–64].
Evidence is emerging that IL-6 can directly affect lipid metabolism and activate pathways to
promote increased energy turnover. Several reports indicate lipolytic properties of IL-6. IL-6
has been shown to stimulate lipolysis in humans, also increasing free fatty acid
concentrations and whole body fat oxidation [65–67]. In addition, IL-6 increases lipolysis
and significantly lowers adipose tissue lipoprotein lipase (LPL) activity in both cultured
adipocytes in vitro and mice in vivo [68–70]. Despite discrepancies regarding the effects of
IL-6, it can be inferred that overabundance of adipose tissue-derived IL-6 has significant
effects on body weight and lipid metabolism. Several findings have shown that IL-6 can also
affect other adipokines. Notably, IL-6 can decrease the expression and secretion of
adiponectin in human adipocytes, as well as other markers of adipocyte differentiation [30;
71; 72]. Overall, IL-6 may play a pivotal role in metabolic diseases, including obesity.
Therefore, understanding and clarifying its role in the regulation of metabolism has merit.
CILIARY NEUROTROPHIC FACTOR
Ciliary neurotrophic factor (CNTF) is a neurocytokine expressed by glial cells in peripheral
nerves and in the central nervous system that was originally identified for its role in the
differentiation and survival of neuronal cell types (reviewed in [73]). During a clinical trial
evaluating the effects of CNTF on progression of the neurodegenerative disease
amyotrophic lateral sclerosis, researchers discovered that CNTF treated patients underwent
marked weight loss [74]. Since this discovery, CNTF has been intensely investigated to
characterize its anti-obesigenic properties.
CNTF treatment of mice reduces adiposity and body weight and improves diabetic
parameters in both genetic and diet-induced models of obesity/T2DM [75–77]. Hence,
CNTF provided a cytokine-mediated anti-obesity effect that could act independently of
leptin and circumvent leptin-resistance. Due to these profound effects, a human recombinant
variant of CNTF, Axokine, was engineered and administered to patients in a series of
clinical trials. Axokine was shown to induce weight loss in human subjects [78], as well as
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rodent models of obesity [79]. Importantly, Axokine decreased food intake, increased
energy expenditure, and caused a sustained reduction in body weight. The beneficial effects
of human recombinant CNTF in obese/T2DM rodents included a reduction in white adipose
tissue fat mass, body weight, blood glucose, serum free fatty acids, and pancreatic islet
triacylglycerides, as well as enhanced expression of genes associated with energy
metabolism in brown adipose tissue [80]. CNTF was recognized as a therapeutic target for
obesity and the focus of extensive research to elucidate its potential effects on metabolic
pathways and mechanisms of action.
In addition to direct effects of CNTF on the CNS, studies have shown that CNTF may
directly act on cells from peripheral tissues to modulate lipid and energy metabolism via a
centrally-independent manner. In mouse brown adipocytes, CNTF directly activates several
important metabolic signaling proteins and pathways including STAT3, MAPK, Akt, and
p70 S6 kinase [81]. Functionally, CNTF enhanced the induction of uncoupling-protein 1,
providing evidence for a peripheral role in regulating energy homeostasis. In addition,
CNTF activates STAT3 in both cultured adipocytes in vitro and white adipose tissue in vivo
in rodents [22]. Importantly, CNTF treatment conferred insulin sensitivity in cultured
murine adipocytes and resulted in increased glucose transporter-4 (GLUT4) and insulin
receptor substrate-1 (IRS-1) expression and activation [22]. In addition, CNTF receptor
expression was substantially induced in fat pads of numerous rodent models of obesity/
T2DM [22], which may suggest a compensatory role for this cytokine to enhance insulin
sensitivity. The first evidence to strongly suggest that CNTF could act in a centrally
independent manner showed that intraperitoneally (IP), but not intracerebroventricularly
(ICV), delivered CNTF induced various metabolic signaling pathways, as well as promoted
insulin sensitivity and fatty acid oxidation via an AMP-activated protein kinase (AMPK)-
dependent mechanism in skeletal muscle of mice fed a high fat diet [82]. Additional findings
highlight the cellular and molecular mechanisms by which CNTF causes fat loss. Recent
studies have shown that CNTF-mediated reductions in adipose tissue mass in rats resulted
from decreased adipocyte area and triglyceride content and enhanced fatty acid oxidation
[83]. Other studies indicate that CNTF reduced adipose tissue mass in rats via apoptosis
[84]. Acute and chronic treatments of CNTF inhibit leptin expression and secretion [85],
indicating that CNTF can modulate adipocyte endocrine function. Overall, CNTF acts both
centrally as well as peripherally to promote weight reduction, insulin sensitivity, and fatty
acid oxidation. Further analyses are required to better understand its potential as a
therapeutic for obesity and Type 2 diabetes.
LEUKEMIA INHIBITORY FACTOR
Leukemia inhibitory factor (LIF) is one of the most studied gp130 cytokines and was
originally indentified for its ability to inhibit the growth of a leukemic cell line. The most
widely recognized function of LIF is its ability to maintain the totipotency of embryonic
stem cells [86]. However, LIF exerts a wide variety of pleitropic actions, including acting as
a stimulus for platelet formation, modulating proliferation of a variety of cell types,
enhancing survival of peripheral neurons, promoting bone formation, and enhancing acute
phase production by hepatocytes. Both adipocytes in vitro and adipose tissue in vivo are
responsive to LIF [19]. Interestingly, LIF was characterized as an inducer of cachetic weight
loss in mice engrafted with a melanoma cell line that overproduces LIF [87]. However, it
was not investigated whether these weight loss effects were mediated by direct effects of
LIF on adipocytes. Subsequently, LIF was found to inhibit lipoprotein lipase (LPL)
expression and activity in 3T3-L1 and 3T3-F442A murine adipocytes, without affecting the
rate of lipogenesis [88]. Proadipogenic effects of LIF have been shown by enhanced activity
of glycerol-phosphate dehydrogenase and accumulation of lipid in Ob1771 cells during
adipogenesis [89]. However, other findings have shown that LIF prevents adipogenesis in
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bone marrow stromal cells [90]. In 3T3-L1 cells, studies indicate that, unlike other gp130
cytokines, LIF does not modulate adipogenesis [24; 27]. Collectively, these studies suggest
that the effects of LIF on adipogenesis vary with the developmental stage of the cells or
tissue. To date, there have been very few studies on the effects of LIF in mature adipocytes
in vitro or on adipose tissue in vivo. In murine adipocytes, chronic LIF treatment does not
induce insulin resistance but decreases the expression of sterol regulatory element binding
protein (SREBP-1) and the levels of stored triacylglycerides [27]. In summary, the studies of
LIF in adipose tissue suggest adipogenesis can be modulated by this gp130 cytokine at
certain stages of development and can control the expression of genes associated with lipid
metabolism.
ONCOSTATIN M
Oncostatin M (OSM) shares two primary similarities with LIF. First, human oncostatin was
identified for its ability to inhibit the growth of cancer lines [91]. Second, OSM shares
substantial sequence identity with LIF [92]. Like other gp130 cytokines, OSM can modulate
a variety of biological processes and has some functional overlap with LIF. It has been
suggested that OSM and LIF evolved by gene duplication relatively recently [93]. Unlike
CT-1 and some other gp130 cytokines, OSM has its own specific receptor that
heterodimerizes with gp130 [94]. The oncostatin receptor, OSMRβ, appears to mediate the
majority of the effects of OSM. Murine adipocytes in vitro and white adipose tissue in vivo
are responsive to OSM and recent studies have shown that OSM can inhibit preadipocyte
differentiation [24; 25]. In mature fat cells, OSM has been shown to inhibit adiponectin
expression [95]. Overall, these studies indicate that OSM has negative effects on fat cells
since it enhances two conditions, inhibition of adipogenesis and reduced adiponectin
expression, which are associated with metabolically unfavorable events in adipocytes and in
the whole organism.
CARDIOTROPHIN-1
Cardiotrophin-1 (CT-1) is a gp130 cytokine family member that was identified in 1995 in a
cDNA library derived from mouse embryoid bodies and was shown to support in vitro
cardiomyocyte survival and hypertrophy [96]. CT-1 is a 200 amino acid protein with a
molecular mass of approximately 21.5 kD [96]. CT-1 mRNA expression has been detected
at high levels in the heart, skeletal muscle, and liver, as well as in fetal heart, lung, and
kidney. Lower amounts have also been detected in a variety of other tissues [96]. Both
functional and receptor binding studies in cultured cardiomyocytes have shown that CT-1
signals through the gp130/LIFR heterodimer without the further requirement for an -subunit
[9; 97]. The majority of studies on CT-1 indicate a role of this gp130 cytokine in a variety of
heart pathologies, including hypertension, myocardial infarction, ischemia, and
cardiomyopathy (reviewed in [98]). Circulating CT-1 levels are readily measured in both
rodents and humans [99–101]. Although rodent adipocytes and adipose tissue are highly
responsive to CT-1 [23; 102], the effects of CT-1 on adipocytes have not been widely
studied. In vitro studies indicate that CT-1 does not inhibit preadipocyte differentiation, but
does induce insulin resistance in mature murine fat cells [23]. Of note, one recent study
suggests that CT-1 is produced in adipose tissue [103]. Overall, these observations suggest
that CT-1 may be a novel and potentially important link between obesity/T2DM and
cardiovascular disease.
NEUROPOIETIN
Neuropoeitin (NP) was characterized as a potential regulator of murine central nervous
system development, with the ability to modulate motor neuron survival in vitro [15]. NP
was shown to be highly expressed in mouse embryonic neuroepithelia [15] and can induce
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neuroepithelial cells to differentiate into astrocytes [104]. Though the analysis of NP action
has been limited to the nervous system, studies from our laboratory have also partially
elucidated the effects and differential roles of NP in murine adipocytes [24]. Our data
indicate that NP is a potent activator of STAT3 and MAPK (ERKs 1 and 2) in both 3T3-L1
adipocytes in vitro and adipose tissue in vivo. Importantly, this cytokine was shown to affect
essential fat cell functions in rodents, such as inhibiting adipocyte differentiation and
attenuating insulin-stimulated glucose uptake and insulin signaling both in vitro and in vivo
[24]. Continued investigation of NP may reveal additional functions in adipose tissue that
have significant metabolic effects.
INTERLEUKIN-11
Interleukin-11 (IL-11) is a bone marrow stromal-derived growth factor that was originally
characterized for its role in hematopoiesis [105]. Subsequent analyses revealed that IL-11
could inhibit adipogenesis of 3T3-L1 preadipocytes and suppress lipoprotein lipase activity
in fully differentiated murine adipocytes [106; 107]. Several additional studies document the
ability of IL-11 to inhibit adipocyte differentiation, as well as the expression of adipogenic
markers [28; 29; 108; 109]. IL-11 has been shown to activate various proteins and signaling
pathways in 3T3-L1 cells, such as STATs 1 and 3, MAPK (ERK), p70 S6 protein kinase,
and phosphatidylinositol 3-kinase (PI3-kinase) [18; 110; 111]. The anti-inflammatory effects
of IL-11 are demonstrated by prevention of streptozotocin-induced diabetes in mice, as well
as the inhibition of inflammatory pathways, specifically nuclear factor kappa- beta (NFκB),
in islets [112]. Additional studies may reveal multiple roles for IL-11 in adipose tissue, such
as regulating the production of secreted inflammatory cytokines that mediate insulin
resistance.
OTHER GP130 CYTOKINES
Cardiotrophin-like cytokine (CLC) was identified as a neurotrophic factor that has B cell
stimulating effects, promotes survival of neuronal cells, and modulates corticotroph cell
function [113; 114]. Though highly expressed in the spleen and lymph nodes, CLC is also
expressed in a variety of other tissues, which suggests important biological roles in cellular
functions (reviewed in [115]). Interleukin- 27 (IL-27) was discovered to be important in
processes such as neuronal growth, bone maintenance, cardiac development, and immune
response regulation (reviewed in [116]). Numerous reports suggest a pleiotrophic nature for
this gp130 cytokine, for IL-27 is associated with both pro- and anti-inflammatory processes.
To date, the effects of CLC and IL-27 in adipose tissue have not been characterized, yet
serum IL-27 levels can be measured [122].
CONCLUSIONS
Though the functions and mechanisms underlying the actions of gp130 cytokines in adipose
tissue have not been fully elucidated, circulating levels of many gp130 cytokines in humans
have been examined and shown to have divergent effects [47–49; 103; 117–122]. In
addition, many gp130 cytokines activate common signaling pathways, including JAK/STAT
and MAPK (ERK), and utilize the same receptor components in adipocytes in vitro and
adipose tissue in vivo. Analysis of gp130 signaling also revealed that gp130 cytokines have
the unique ability to crosstalk with other members of the gp130 family to attenuate one
another's signaling, and this crosstalk is correlated with the degradation of the LIFR via a
lysosome-mediated pathway [102]. Additional studies from our laboratory provide evidence
for this inhibitory crosstalk in white adipose tissue in vivo (unpublished). The fact that
gp130 cytokines not only activate signaling pathways in vivo, but also inhibit subsequent
signaling of other gp130 family members confirms that a detailed analysis of crosstalk
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mechanisms and interactions is relevant for a more detailed perspective of gp130 cytokine
secretion and action.
Further studies are needed to examine how gp130 cytokines could possibly contribute to or
affect metabolic disease states that are characterized by the expression of multiple cytokines,
including those belonging to the gp130 family. Adipose tissue is comprised of various cell
types. Recent studies have shown the presence of a variety of immune cells (macrophages, T
cells) that are present in adipose tissue and regulated by pathological conditions (obesity,
insulin resistance, Type 2 diabetes). The production of gp130 cytokines from these immune
cells is an unexplored area of inflammation and metabolic diseases. Nonetheless, as
described above and summarized in Tables 2 and 3, several gp130 cytokines have profound
effects on adipocyte differentiation and insulin sensitivity in mature fat cells. The
differential response of adipocytes to gp130 cytokines cannot be explained by their receptor
components, suggesting that other proteins must play a role in mediating the specificity of
these cytokines. A greater understanding of the diverse actions of gp130 cytokines in
adipose tissue is important and will be essential in understanding the functions and sources
of these cytokines and may also provide valuable information in the potential development
of novel therapeutic strategies.
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Table 2
The Effect of gp130 Cytokines on Adipocyte Differentiation
gp 130 Cytokine Effect on Adipogenesis Reference(s)
CNTF No effect [22]
CT-1 No effect [23]
IL-11 Inhibitory [28, 29, 106, 107]
LIF Controversial
Pro-adipogenic 89
No effect 24, 27
Anti-adipogenic 90
NP Inhibitory [24]
OSM Inhibitory [24, 25]
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Table 3
The Effect of gp130 Cytokines on Insulin Sensitivity in Adipocytes.
gp 130 Cytokine Effect on Insulin Action Reference(s)
CNTF Insulin sensitizer [22, 75,77]
CT-1 Induce insulin resistance [23]
IL-6 Controversial [20, 21, 45–61]
LIF No effect [27]
NP Induce insulin resistance [24]
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